Jade Biosciences, Inc.
JBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001798749
No open-market purchases or sales by Jade Biosciences, Inc. insiders were filed in the last 90 days; 153 institutions reported holding it in 13F filings for Q2 2026, worth $1.62B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +35 vs. previous quarter
- 153
- 13F valueReported value at the end of Q2 2026
- $1.62B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding JBIO, Q2 2026
No superinvestor reported holding JBIO at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Jade Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 19, 2025 (view filing) | May 16 | 3 days | Frohlich TomChief Executive Officer | PPurchase | +6.00K | $7.40 | +$44.4K | New position6.00K after | |
| Jun 20, 2024 (view filing)5:56 PM ET | Jun 17 | 3 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchase | +928.1K | $1.67 | +$1.55M | +13.3%7.89M after | |
| Jun 14, 2024 (view filing) | Jun 14 | Same day | Eldridge George ASEE REMARKS | SSale | −15.0K | $25.03 | −$375.4K | −74.9%5.02K after | 10b5-1 |
| Jun 14, 2024 (view filing) | Jun 14 | Same day | Verwijs MarinusCHIEF TECHNICAL OFFICER | SSale | −10.6K | $25.00 | −$265.0K | −100.0%0 after | 10b5-1 |
| Jun 14, 2024 (view filing) | Jun 13 | 1 day | Gillies HunterCHIEF MEDICAL OFFICER | SSale | −6.00K | $24.50 | −$147.0K | −51.7%5.60K after | 10b5-1 |
| May 17, 2024 (view filing) | May 17 | Same day | Gillies HunterCHIEF MEDICAL OFFICER | SSale | −4.00K | $21.09 | −$84.3K | −41.7%5.60K after | 2 lots10b5-1 |
| May 17, 2024 (view filing) | May 16 | 1 day | Noyes Timothy PCHIEF EXECUTIVE OFFICER | SSale | −10.0K | $21.57 | −$215.7K | −100.0%0 after | 2 lots10b5-1 |
| May 3, 2024 (view filing) | May 2 | 1 day | Verwijs MarinusCHIEF TECHNICAL OFFICER | SSale | −1.98K | $21.02 | −$41.6K | −100.0%0 after | |
| May 3, 2024 (view filing) | May 1 | 2 days | Noyes Timothy PCHIEF EXECUTIVE OFFICER | SSale | −11.4K | $20.33 | −$230.9K | −100.0%0 after | 3 lots10b5-1 |
| Apr 19, 2024 (view filing) | Apr 17 | 2 days | Dake Benjamin TSEE REMARKS | SSale | −6.85K | $22.38 | −$153.4K | −84.1%1.29K after | 3 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Jade Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 9,126,877 | $202.8M | 0.01% | +2,041,454+28.8% | Added |
| Jupiter Topco LLC | 6,273,262 | $139.4M | 0.06% | +6,273,262 | New |
| Fairmount Funds Management LLC | 4,553,494 | $101.2M | 6.69% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 3,671,083 | $81.6M | 0.71% | 00.0% | Unchanged |
| VR Adviser, LLC | 3,220,364 | $71.6M | 2.17% | 00.0% | Unchanged |
| Bellevue Group AG | 3,057,996 | $67.9M | 1.43% | −443,506−12.7% | Reduced |
| Paradigm Biocapital Advisors LP | 2,857,405 | $63.5M | 1.19% | +2,857,405 | New |
| BlackRock, Inc. | 2,801,451 | $62.2M | 0.00% | +487,502+21.1% | Added |
| Franklin Resources Inc | 2,792,080 | $62.0M | 0.01% | +2,792,080 | New |
| State Street Corp | 2,335,285 | $51.9M | 0.00% | +1,679,595+256.2% | Added |